Bristol-Myers Squibb Company (NYSE:BMY) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 6, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...
No-Moat Lundbeck's Strategic Brands Drive Growth but Face Generic Pressure Amid Patent Losses
However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...
Knowridge18h
Cannabis use linked to schizophrenia, study shows
A new study from Canadian researchers has found that the proportion of new schizophrenia cases associated with cannabis use ...
Model Portfolio For Capital Appreciation, February 2025
Top stock picks for capital appreciation and outperformance, with a focus on profits, dividends, and long-term viability. Click for more on Capital Appreciation.
Healio7h
Researchers stress need for clear, consistent standards in FDA review of psychiatric drugs
The FDA approved 16 psychiatric drugs over the last decade, most of which shared similar mechanisms of action with previously ...
Q4 2024 Bristol-Myers Squibb Co Earnings Call
Christopher Boerner; Chairman of the Board, Chief Executive Officer, Chief Operating Officer; Bristol-Myers Squibb Co David Elkins; Executive Vice President, Chief Financial Officer, Member of the ...